Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHLOROQUINE PHOSPHATE vs ARALEN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive strains,Treatment of extraintestinal amebiasis (as an adjunct),Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label),Treatment of porphyria cutanea tarda (off-label)
Treatment of uncomplicated malaria due to chloroquine-sensitive Plasmodium species,Prophylaxis of malaria in areas with chloroquine-sensitive parasites,Extraintestinal amebiasis,Treatment of discoid lupus erythematosus (off-label),Treatment of rheumatoid arthritis (off-label)
600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.
Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.
Terminal elimination half-life: 30-60 days (range 20-100 days); prolonged due to extensive tissue distribution and slow release from lysosomes.
48-72 hours (terminal elimination half-life); prolonged to weeks with chronic dosing due to extensive tissue accumulation, especially in the liver, spleen, and melanin-containing tissues.
Hepatic metabolism via CYP2C8 and CYP3A4 to major metabolite desethylchloroquine; other minor metabolites. Renal excretion of parent drug and metabolites.
Hepatic metabolism via CYP2C8, CYP3A4, and CYP2D6 to desethylchloroquine and other metabolites.
Renal: 50-70% as unchanged drug; hepatic/biliary: 20-30% as metabolites; fecal: up to 20%.
Renal (~70% unchanged), with 10-20% in feces; biliary elimination is minor.
50-60% bound to plasma proteins, primarily albumin.
50-60%, primarily to albumin and α1-acid glycoprotein.
Vd: 100-150 L/kg (range 50-200 L/kg); extremely large indicating extensive tissue penetration and accumulation.
50-100 L/kg; extensive tissue sequestration including erythrocytes, liver, spleen, and melanin-containing tissues like skin and retina.
Oral: 80-90% (rapidly absorbed from GI tract); bioavailability is nearly complete with food enhancing absorption.
Oral: ~70-80% (variable due to first-pass metabolism); intravenous: 100%.
For Cr Cl <10 m L/min: use 50% of normal dose. For Cr Cl 10-50 m L/min: no adjustment required. For intermittent hemodialysis: no supplemental dose needed.
Severe renal impairment (GFR <10 m L/min): reduce dose by 50% or increase dosing interval.
Severe impairment (Child-Pugh C): maximum 300 mg base (500 mg phosphate) every 12 hours; monitor for toxicity. Mild to moderate impairment: no adjustment needed.
Use with caution in patients with hepatic impairment; no specific dose adjustment guidelines available; contraindicated in severe hepatic disease or porphyria.
For malaria: 10 mg base/kg (16.7 mg phosphate/kg) orally once daily for 2 days, then 5 mg base/kg (8.3 mg phosphate/kg) orally once daily for 3 days. Maximum single dose: 600 mg base (1 g phosphate). For extraintestinal amebiasis: 10 mg base/kg (16.7 mg phosphate/kg) orally once daily for 2-3 weeks (max 300 mg base/day).
Prophylaxis: 5 mg base/kg orally once weekly (max 300 mg base). Treatment: 10 mg base/kg orally initially, then 5 mg base/kg at 6, 24, and 48 hours (max 600 mg base total).
No specific dose adjustment; use with caution due to increased risk of QT prolongation and accumulation with renal impairment. Consider lower initial dose and monitor renal function.
Start at lower end of dosing range due to increased risk of adverse effects (e.g., QT prolongation, retinal toxicity); monitor renal function.
None explicitly required in current FDA labeling for chloroquine; however, serious adverse effects such as irreversible retinal damage, cardiac toxicity, and hypoglycemia are well-documented. Not receiving a black box warning in standard product labeling.
No FDA black box warning.
Retinopathy: irreversible retinal damage with prolonged use; baseline and periodic ophthalmologic exams recommended for chronic therapy.,Cardiac toxicity: QTc prolongation, ventricular arrhythmias, cardiomyopathy; avoid in patients with pre-existing cardiac conditions or concurrent QTc-prolonging drugs.,Hypoglycemia: can cause severe hypoglycemia, especially in diabetics.,Neuropsychiatric effects: seizures, psychosis, suicidal ideation.,Hematologic toxicity: agranulocytosis, aplastic anemia (rare).,Hepatotoxicity: elevated liver enzymes, hepatic failure.,Ototoxicity: irreversible hearing loss.,G6PD deficiency: hemolytic anemia risk with acute hemolysis.
Retinopathy and irreversible retinal damage with prolonged use or high doses; requires baseline and periodic ophthalmologic exams,QT prolongation and ventricular arrhythmias, especially with concomitant QT-prolonging drugs or electrolyte abnormalities,Severe hypoglycemia including loss of consciousness,Neuropsychiatric effects including psychosis and suicidal ideation,Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or visual field changes,Pregnancy (especially first trimester) due to potential fetal harm; use for malaria only if benefit outweighs risk,Lactation: caution, excreted in breast milk,G6PD deficiency (relative contraindication; may cause hemolysis)
Hypersensitivity to chloroquine or any 4-aminoquinoline,Pre-existing retinopathy or known maculopathy,Known G6PD deficiency (relative, use with caution),Concomitant use with strong QT-prolonging drugs (e.g., quinidine, procainamide)
No specific food restrictions. Absorption enhanced by food; take with meals to reduce GI upset. Avoid grapefruit juice if QT prolongation concern.
Avoid grapefruit and grapefruit juice as they may increase drug levels and toxicity. Limit alcohol intake to reduce risk of liver toxicity. Administer with food to decrease gastrointestinal irritation. Avoid antacids containing aluminum or magnesium; separate by at least 4 hours.
Chloroquine phosphate crosses the placenta. First trimester: limited data suggest no major increase in congenital malformations, but risk cannot be excluded. Second and third trimesters: no specific fetal risks documented at standard doses; however, high doses (e.g., for malaria treatment) may cause retinal toxicity or ototoxicity. Overall, considered low teratogenic risk, but benefit-risk assessment required.
Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) at high doses. Second and third trimesters: possible ototoxicity and retinal toxicity; use only for malaria prophylaxis or treatment when benefit outweighs risk.
Chloroquine is excreted into breast milk in small amounts (M/P ratio approximately 0.3-0.5). Infant dose is estimated <5% of maternal weight-adjusted dose. No adverse effects in breastfed infants reported. Considered compatible with breastfeeding.
Chloroquine is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Amounts are unlikely to cause adverse effects in nursing infants. The American Academy of Pediatrics considers chloroquine compatible with breastfeeding. Monitor infant for potential ocular effects.
No dose adjustment required for prophylaxis or treatment of malaria in pregnancy (standard adult dosing). For autoimmune indications (e.g., lupus, rheumatoid arthritis), maintain lowest effective dose (e.g., 250 mg daily of chloroquine base equivalent). Increased clearance in pregnancy may necessitate therapeutic drug monitoring in rare cases, but standard dosing is typically sufficient.
Increased volume of distribution and clearance during pregnancy may require higher doses for malaria prophylaxis (e.g., 400 mg base weekly) and treatment; therapeutic drug monitoring recommended for optimal dosing. No standard dose adjustment established; base dose on indication and clinical response.
Chloroquine has a narrow therapeutic index; toxicity can cause retinopathy, especially with cumulative doses >460g base. Baseline and annual eye exams are mandatory. For acute malaria, may need loading dose. Contraindicated in G6PD deficiency due to hemolysis risk. QT prolongation possible; avoid with other QT-prolonging drugs.
ARALEN HYDROCHLORIDE (chloroquine hydrochloride) is used for malaria prophylaxis and treatment, and for amebiasis. Monitor for retinal toxicity with long-term use; baseline and periodic ophthalmologic exams recommended. Caution in patients with hepatic disease, G6PD deficiency, or porphyria. May exacerbate psoriasis and myasthenia gravis. QT prolongation possible; avoid with other QT-prolonging drugs. Administer with food to reduce GI upset. For acute malaria, dose may be divided to improve tolerance. In severe malaria, use parenteral form with cardiac monitoring.
Take exactly as prescribed; do not miss doses or double up.,Can cause blurred vision; avoid driving until vision clears.,Report vision changes, hearing loss, or unusual bleeding immediately.,May cause GI upset; take with food or milk.,Finishing full course is critical even if symptoms improve.,Use sunscreen; may increase sensitivity to sunlight.
Take this medication exactly as prescribed; do not skip doses for malaria prophylaxis.,If vomiting occurs within 1 hour of a dose, contact your healthcare provider for instructions.,Report any vision changes, such as blurred vision or difficulty focusing, immediately.,Avoid alcohol and limit caffeine intake as they may increase gastrointestinal side effects.,Use effective contraception during treatment if you are of childbearing potential.,Do not take antacids or kaolin within 4 hours of this medication.,Seek medical attention if you experience signs of allergic reaction: rash, hives, swelling, or difficulty breathing.
"The coadministration of alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with chloroquine may lead to increased plasma concentrations of chloroquine. This occurs because alogliptin potentially inhibits CYP2C8 and/or CYP3A4, the cytochrome P450 enzymes responsible for chloroquine metabolism. As a result, patients may be at higher risk for chloroquine-related adverse effects such as cardiac arrhythmias (QT prolongation), retinopathy, and hypoglycemia."
"Chloroquine inhibits CYP2C8, CYP2D6, and CYP3A4, key enzymes responsible for the metabolism of nilotinib. This inhibition can significantly increase nilotinib plasma concentrations, elevating the risk of severe adverse effects such as QTc prolongation, hepatotoxicity, and myelosuppression. Concurrent use may also exacerbate the risk of cardiotoxicity, including arrhythmias and sudden cardiac death, due to additive effects on cardiac repolarization."
"Amiloride, a potassium-sparing diuretic, may reduce the antihypertensive efficacy of chloroquine, an antimalarial agent. This interaction arises from amiloride's inhibition of renal tubular sodium reabsorption, which can alter electrolyte balance and potentially blunt the hypotensive effects of chloroquine, leading to suboptimal blood pressure control. In clinical practice, this may result in diminished antihypertensive response, requiring dose adjustments or alternative therapies."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHLOROQUINE PHOSPHATE vs ARALEN HYDROCHLORIDE, answered by our medical review team.
CHLOROQUINE PHOSPHATE is a Antimalarial that works by Chloroquine is a 4-aminoquinoline that acts as a blood schizonticide. It inhibits heme polymerase in malaria parasites, preventing the conversion of toxic heme to hemozoin, leading to accumulation of toxic heme and parasite death. It also has anti-inflammatory and immunomodulatory effects via inhibition of toll-like receptors and cytokine production.. ARALEN HYDROCHLORIDE is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as lysosomes and food vacuoles of malaria parasites, raising p H and inhibiting hemozoin polymerization, which leads to toxic heme accumulation and parasite death. It also has anti-inflammatory and immunomodulatory effects by inhibiting TLR signaling and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHLOROQUINE PHOSPHATE and ARALEN HYDROCHLORIDE depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHLOROQUINE PHOSPHATE is: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 3 days for malaria. For extraintestinal amebiasis: 600 mg base (1 g phosphate) orally once daily for 2 days, then 300 mg base (500 mg phosphate) orally once daily for 2-3 weeks.. The standard adult dose of ARALEN HYDROCHLORIDE is: Chloroquine phosphate 500 mg (300 mg base) orally once weekly for prophylaxis; 600 mg base (1 g phosphate) orally initially, followed by 300 mg base (500 mg phosphate) at 6, 24, and 48 hours for treatment of malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHLOROQUINE PHOSPHATE and ARALEN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHLOROQUINE PHOSPHATE is classified as Category C. Chloroquine phosphate crosses the placenta. First trimester: limited data suggest no major increase in congenital malformations, but risk cannot be excluded. Second and third trime. ARALEN HYDROCHLORIDE is classified as Category C. Chloroquine hydrochloride crosses the placenta. First trimester: associated with increased risk of spontaneous abortion and congenital abnormalities (cochleovestibular and ocular) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.